BioCryst Pharmaceuticals Stock News

Two biotechs with COVID-19 programs. One has been the bigger winner so far this year -- but does that make it the better pick going forward?

Geode Capital Management LLC increased its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 28.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities

Drugmakers across the globe are rushing to develop a treatment or vaccine for the fast-spreading coronavirus that has wreaked havoc across the globe, killing over 191,000 people and ravaging financial

BioCryst files $500M mixed securities shelf BCRX

BioCryst Pharmaceuticals Inc:

Gilead sinks 6% to $76.28 after FT says remdesivir failed in first trial GILD

Gilead's remdesivir disappoints in first clinical trial, FT reports GILD

Markets move lower after FT report of failed Gilead COVID-19 trial SPX SPY GILD

Treasury announced a $120 B 3-pronged package of shorter coupon auctions

UniCredit price target lowered to EUR 8.50 from EUR 16 at Deutsche Bank Deutsche Bank UNCRY

Intesa Sanpaolo price target lowered to EUR 1.70 from EUR 3 at Deutsche Bank Deutsche Bank ISNPY

Mediobanca price target lowered to EUR 7.50 from EUR 11.80 at Deutsche Bank Deutsche Bank MDIBY

Banco de Sabadell price target lowered to EUR 0.55 at Deutsche Bank Deutsche Bank BNDSF

Banco Santander price target lowered to EUR 2.98 from EUR 3.90 at Deutsche Bank Deutsche Bank SAN

BBVA price target lowered to EUR 4.05 from EUR 5.60 at Deutsche Bank Deutsche Bank BBVA